People: Synageva BioPharma Corp (GEVA.O)

GEVA.O on Nasdaq

71.42USD
1:29pm EDT
Price Change (% chg)

-- (+0.00%)
Prev Close
$71.42
Open
$72.00
Day's High
$73.55
Day's Low
$71.24
Volume
134,051
Avg. Vol
285,379
52-wk High
$119.42
52-wk Low
$44.52

Search Stocks

Malley, Thomas 

Brief Biography

Mr. Thomas R. Malley is Independent Director of Synageva Biopharma Corp since November 2, 2011. prior to that time served as a director of Private Synageva since October 2006. Since May 2007, Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm. From December 1998 to May 2007, Mr. Malley served with Janus Mutual Funds, including as Vice President and Portfolio Manager for the Janus Global Life Sciences Fund. From April 1991 to December 1998, Mr. Malley served as an equity analyst for Janus Mutual Funds. Mr. Malley previously served as a director of Cougar Biotechnology, Inc. from 2007 to 2009, which was a publicly traded company until Johnson & Johnson acquired the company in 2009. Mr. Malley also previously served as a director of Craig Hospital, a non-profit hospital, from 2007 to 2013 and St. Anthony Hospital, a non-profit hospital, from 2004-2009. Mr. Malley is also a director of Puma Biotechnology, Inc. and OvaScience, Inc. two publicly traded biotechnology companies, and is also a director of Project Cure, a non-profit organization. Mr. Malley holds a B.S. in Biology from Stanford University. Mr. Malley’s industry and investment experience benefits the Board of Directors.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Felix Baker

--

Sanj Patel

3,878,120

Carsten Boess

1,513,440

Mark Goldberg

1,565,720

Anthony Quinn

1,566,510

Ulrich Goldmann

--
As Of 30 Dec 2013
Search Stocks